[Skip to Navigation]
Sign In
Medical News & Perspectives
July 21, 2021

Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered

JAMA. 2021;326(6):469-472. doi:10.1001/jama.2021.11558

The Food and Drug Administration’s (FDA’s) approval June 7 of the drug aducanumab was notable for a number of reasons:

Neurologist Allan Levey, MD, PhD, director of Emory University’s Goizueta Alzheimer Disease Research Center, was blunt in his assessment of aducanumab, sold under the brand name Aduhelm and marketed by Biogen, based in Cambridge, Massachusetts, and Eisai, headquartered in Tokyo.

Add or change institution